Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseasesopen access
- Lee, Han Ah; Chang, Young; Sung, Pil Soo; Yoon, Eileen L.; Lee, Hye Won; Yoo, Jeong-Ju; Lee, Young-Sun; An, Jihyun; Song, Do Seon; Cho, Young Youn; Kim, Seung Up; Kim, Yoon Jun
- Issue Date
- Nonalcoholic fatty liver disease; Viral hepatitis; Cirrhosis; Non-antidiabetic drugs; Treatment
- Clinical and Molecular Hepatology, v.28, no.3, pp.425 - 472
- Journal Title
- Clinical and Molecular Hepatology
- Start Page
- End Page
- The global burden of chronic liver disease (CLD) is substantial. Due to the limited indication of and accessibility to antiviral therapy in viral hepatitis and lack of effective pharmacological treatment in nonalcoholic fatty liver disease, the beneficial effects of antidiabetics and non–antidiabetics in clinical practice have been continuously investigated in patients with CLD. In this narrative review, we focused on non-antidiabetic drugs, including ursodeoxycholic acid, silymarin, dimethyl4,4’-dimethoxy-5,6,5’,6’-dimethylenedixoybiphenyl-2,2’-dicarboxylate, L-ornithine L-aspartate, branched chain amino acids, statin, probiotics, vitamin E, and aspirin, and summarized their beneficial effects in CLD. Based on the antioxidant, anti-inflammatory properties, and regulatory functions in glucose or lipid metabolism, several non–antidiabetic drugs have shown beneficial effects in improving liver histology, aminotransferase level, and metabolic parameters and reducing risks of hepatocellular carcinoma and mortality, without significant safety concerns, in patients with CLD. Although the effect as the centerpiece management in patients with CLD is not robust, the use of these non-antidiabetic drugs might be potentially beneficial as an adjuvant or combined treatment strategy.
- Files in This Item
- There are no files associated with this item.
- Appears in
- 2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.